<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501644</url>
  </required_header>
  <id_info>
    <org_study_id>ID02-231</org_study_id>
    <nct_id>NCT00501644</nct_id>
  </id_info>
  <brief_title>Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of Chemoimmunotherapy for Patients With Potentially Platinum Sensitive Müllerian (Epithelial Ovarian, Peritoneal, or Fallopian Tube) Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. Determine response rate, time to progression, and toxicity of a schedule of carboplatin&#xD;
           by IV (intravenous) infusion, GM-CSF and rIFN-g by SC (subcutaneous injection) in&#xD;
           patients with potentially platinum-sensitive recurrent Müllerian carcinomas.&#xD;
&#xD;
        2. Determine whether this treatment schedule is associated with:&#xD;
&#xD;
             1. increased levels of monocytes (&gt;2-fold and absolute numbers 1000 cells/ml,) and of&#xD;
                LN-DR+ DC (CD11c+ and CD123+ subsets)&#xD;
&#xD;
             2. induction of priming and activation of MO/MA (monocytes/ macrophages), and&#xD;
                maturation of DC (dendritic cells).&#xD;
&#xD;
        3. Determine the toxicity profile of consolidation treatment with IP (intraperitoneal)&#xD;
           injections of rIFN-g added to carboplatin (IV) and GM-CSF (SC) for 4 doses/course.&#xD;
&#xD;
        4. Determine the effects of carboplatin plus GM-CSF and rIFN-g on quality of life in&#xD;
           patients with platinum-sensitive Müllerian carcinomas.&#xD;
&#xD;
        5. To begin an exploration of cell surface proteins on purified activated peripheral blood&#xD;
           and ascites monocyte/macrophages both before and after treatment with GM-CSFand rIFN-g.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carboplatin is a chemotherapy drug that is used for the treatment of ovarian cancer. GM-CSF&#xD;
      is a protein that is used to increase the production of white blood cells. rIFN-g is a&#xD;
      protein that stimulates cells of the immune system.&#xD;
&#xD;
      Participants will need to have pre-study blood work (about 4 teaspoons) as part of their&#xD;
      evaluation for study entry. In addition, a chest x-ray and CT scan of the abdomen and pelvis&#xD;
      will need to be done before any treatments.&#xD;
&#xD;
      Participants in this study will receive a frequently used dose of carboplatin by vein over 1&#xD;
      hour every 28 days. In addition, GM-CSF will be given for 7 days and rIFN-g will be given for&#xD;
      2 days before and after chemotherapy. Both drugs will be given as injections under the skin.&#xD;
      They will be repeated with each chemotherapy course that participants receive.&#xD;
&#xD;
      GM-CSF and rIFN-g are being used to try to stimulate the immune system in the belief that&#xD;
      this adds to the effectiveness of the chemotherapy on the tumor. During each course of&#xD;
      chemotherapy treatment, blood samples will be taken in order to evaluate the blood count&#xD;
      response to GM-CSF. Participants will need to remain in the Houston area beginning with the&#xD;
      first injection of GM-CSF and for up to 9 days following the carboplatin infusion for the&#xD;
      first course.&#xD;
&#xD;
      QOL forms will be completed at 5 separate time points during the first course of&#xD;
      chemotherapy. Later courses will only have 2 time points for completion of the QOL forms. The&#xD;
      completion of these forms will help researchers to evaluate the effects of the carboplatin&#xD;
      and the 2 proteins on participants and their quality of life.&#xD;
&#xD;
      Participants will receive 3 courses of treatment (each course will include 1 treatment with&#xD;
      carboplatin followed by 2 separate treatment cycles with GM-CSF and rIFN-g) and then be&#xD;
      evaluated for tumor response. If the tumor is responding, 3 additional courses will be given.&#xD;
      If after 6 courses of treatment, the tumor has completely responded and there is no evidence&#xD;
      of the disease, then up to 4 additional courses can be given for completion of therapy. If&#xD;
      the tumor is still responding after 6 courses but has not completely gone away, then&#xD;
      additional courses can be given as long as the tumor is responding before completion therapy&#xD;
      can be considered.&#xD;
&#xD;
      Completion therapy will include carboplatin given every 28 days by vein along with injections&#xD;
      of GM-CSF under the skin before and after the chemotherapy. Injections of rIFN-g will be&#xD;
      given directly into the abdomen through an abdominal catheter if possible. If this is not&#xD;
      possible, then the rIFN-g will be given as injections under the skin. Participants may choose&#xD;
      not to receive the rIFN-g through a catheter during the completion phase and can continue to&#xD;
      receive it under the skin with the chemotherapy. A maximum of 4 additional courses can be&#xD;
      given during this phase of the study.&#xD;
&#xD;
      Participants whose disease gets worse will be taken off the study. Participants who have&#xD;
      intolerable side effect from the study drugs will also be taken off the study treatment.&#xD;
      Participants will have follow up CT scans after every 3 courses of treatment. Following&#xD;
      completion of all treatments, participants will need to return to M. D. Anderson every 3&#xD;
      months for follow-up exams. This will include a physical exam, blood work, and a CT scan.&#xD;
&#xD;
      This is an investigational study. A total of 65 patients will take part in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Response</measure>
    <time_frame>Follow up CT scans after every 3 courses of treatment and following completion of all treatments.</time_frame>
    <description>Per World Health Organization (WHO) Tumor Response: Complete Response (CR), Partial Response (PR) or Progressive Disease (PD). CR defined as disappearance of all target lesions, PR as &gt; = 30% decrease in sum of longest dimensions of target lesions with reference baseline sum longest dimensions and if CA 125 levels declined by &gt;50%, provided target lesion size did not increase by &gt;20% on imaging, and PD as &gt;20% increase in sum of longest dimensions of target lesions taking as references smallest sum of longest dimensions recorded since treatment started, or appearance of 1 or &gt; new lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoimmunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC of 5 by 1 hour IV infusion every 28 days.</description>
    <arm_group_label>Chemoimmunotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF (Sargramostim)</intervention_name>
    <description>Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.</description>
    <arm_group_label>Chemoimmunotherapy</arm_group_label>
    <other_name>Sargramostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Gamma</intervention_name>
    <description>0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).</description>
    <arm_group_label>Chemoimmunotherapy</arm_group_label>
    <other_name>rIFN-g</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Müllerian carcinomas (primary epithelial ovarian, primary peritoneal, or&#xD;
             fallopian tube) who have had a response to platinum-based chemotherapy and have a&#xD;
             chemotherapy treatment-free interval of at least 6 months. These patients are&#xD;
             designated potentially platinum-sensitive.&#xD;
&#xD;
          2. Measurable disease by radiological or clinical examination parameters.&#xD;
&#xD;
          3. No prior immunotherapy.&#xD;
&#xD;
          4. No concurrent steroids or radiation therapy.&#xD;
&#xD;
          5. Adequate hematological parameters (ANC &gt;/= 1500 cells/UL, platelets &gt;/= 100,000&#xD;
             cells/UL&#xD;
&#xD;
          6. Adequate renal function (serum creatinine &lt;/= 1.5 mg/dl)&#xD;
&#xD;
          7. Adequate hepatic function (serum bilirubin &lt;/= 1.5 mg/dl)&#xD;
&#xD;
          8. SGOT or SGPT &lt;/= 2.5 normal&#xD;
&#xD;
          9. Zubrod status &lt;/= 2&#xD;
&#xD;
         10. Signed informed consent&#xD;
&#xD;
         11. Patients with no more than 2 prior therapy regimens (1st line platinum and platinum&#xD;
             reinduction will count as one)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Patients with brain metastases&#xD;
&#xD;
          3. Serum albumin &lt;3 gm/dl&#xD;
&#xD;
          4. Weight loss &gt;10% over 4 months&#xD;
&#xD;
          5. Radiation therapy to whole abdomen&#xD;
&#xD;
          6. History of clinical or EKG findings suggestive of active (within the last 6 months)&#xD;
             heart disease&#xD;
&#xD;
          7. Patients with active autoimmune or inflammatory bowel disease&#xD;
&#xD;
          8. Patients with an active serious infection or other serious underlying medical&#xD;
             condition that would otherwise impair their ability to receive protocol treatment.&#xD;
&#xD;
          9. Dementia or significantly altered mental status that would prohibit the understanding&#xD;
             and/or giving of informed consent.&#xD;
&#xD;
         10. Patients with prior hypersensitivity to platinum agents&#xD;
&#xD;
         11. Patients with history of other malignancy, with the exception of non-melanomatous skin&#xD;
             cancer; unless in complete remission and off therapy for a minimum of 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Freedman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <reference>
    <citation>Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS. Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med. 2006 Apr 7;4:16.</citation>
    <PMID>16603073</PMID>
  </reference>
  <results_reference>
    <citation>Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May;113(2):210-5. doi: 10.1016/j.ygyno.2009.02.007. Epub 2009 Mar 4.</citation>
    <PMID>19264351</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <results_first_submitted>December 23, 2010</results_first_submitted>
  <results_first_submitted_qc>December 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Müllerian Carcinomas</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <keyword>Epithelial Ovarian</keyword>
  <keyword>Peritoneal</keyword>
  <keyword>Fallopian Tube</keyword>
  <keyword>Chemoimmunotherapy</keyword>
  <keyword>Platinum Sensitive Müllerian</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>Sargramostim</keyword>
  <keyword>Interferon Gamma</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>QOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 01/07/03 to 07/25/07. All patients were recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemoimmunotherapy</title>
          <description>GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemoimmunotherapy</title>
          <description>GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="35" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Response</title>
        <description>Per World Health Organization (WHO) Tumor Response: Complete Response (CR), Partial Response (PR) or Progressive Disease (PD). CR defined as disappearance of all target lesions, PR as &gt; = 30% decrease in sum of longest dimensions of target lesions with reference baseline sum longest dimensions and if CA 125 levels declined by &gt;50%, provided target lesion size did not increase by &gt;20% on imaging, and PD as &gt;20% increase in sum of longest dimensions of target lesions taking as references smallest sum of longest dimensions recorded since treatment started, or appearance of 1 or &gt; new lesions.</description>
        <time_frame>Follow up CT scans after every 3 courses of treatment and following completion of all treatments.</time_frame>
        <population>Analysis per protocol. Of 59 participants enrolled, five (5) were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoimmunotherapy</title>
            <description>GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Response</title>
          <description>Per World Health Organization (WHO) Tumor Response: Complete Response (CR), Partial Response (PR) or Progressive Disease (PD). CR defined as disappearance of all target lesions, PR as &gt; = 30% decrease in sum of longest dimensions of target lesions with reference baseline sum longest dimensions and if CA 125 levels declined by &gt;50%, provided target lesion size did not increase by &gt;20% on imaging, and PD as &gt;20% increase in sum of longest dimensions of target lesions taking as references smallest sum of longest dimensions recorded since treatment started, or appearance of 1 or &gt; new lesions.</description>
          <population>Analysis per protocol. Of 59 participants enrolled, five (5) were not evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five years and three months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemoimmunotherapy</title>
          <description>GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>2-Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>5-Grade 3</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>16-Grade 3; 4-Grade 4</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <description>15-Grade 3</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>12-Grade 3; 4-Grade 4</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>9-Grade 3</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <description>2-Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>10-Grade 3</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>2-Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <description>3-Grade 3</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression/Anxiety</sub_title>
                <description>5-Grade 3; 3-Grade 4</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael E. Garcia, RN, BSN</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>mgarcia@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

